00:00
06:37
Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.
Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer. read more read less

10 years ago #advance, #cancergrace, #david, #docetaxel, #dr, #erlotinib, #gerber, #grace, #gracecast, #nsclc, #of, #prose, #proteomics, #study, #tarceva, #taxotere, #texassouthwestern, #university, #verstrat